The role of the tumor stroma in ovarian cancer

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Davidson, Ben ^a,b   Trope, Claes G ^a,b   Reich, Reuven ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Metastasis; Ovarian carcinoma; Prognosis; Stromal myofibroblasts; Tumor progression

Indexed keywords

ANGIOGENIC FACTOR; CATHEPSIN B; CATHEPSIN D; CELL SURFACE RECEPTOR; COLLAGEN TYPE 1; CYTOKINE; DOXORUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; GALECTIN 1; GELATINASE A; GELATINASE B; GROWTH FACTOR; HERMES ANTIGEN; HYALURONIC ACID; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROSTAGLANDIN E SYNTHASE 1; PROTEIN P53; PROTEINASE; RIBONUCLEASE; SURVIVIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR; UROKINASE; VASCULOTROPIN;

ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN SITU HYBRIDIZATION; LEUKOCYTE; METASTASIS; MYOFIBROBLAST; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; STROMA; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84904617133     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00104     Document Type: Review

References (135)

1. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol (2013) 228:1651-7. doi: 10.1002/jcp.24347
2. Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta (2013) 1832:1070-8. doi:10.1016/j.bbadis.2012.10.013
3. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res (2012) 10:1403-18. doi:10.1158/1541-7786.MCR-12-0307
4. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 73:4965-77. doi:10.1158/0008-5472.CAN-13-0661
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin (2012) 62:10-29. doi:10.3322/caac.21149
6. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch (2012) 460:237-49. doi:10.1007/s00428-012-1203-5
7. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet (2009) 374:1371-82. doi:10.1016/S0140-6736(09)61338-6
8. Labiche A, Heutte N, Herlin P, Chasle J, Gauduchon P, Elie N. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma. Int J Gynecol Cancer (2010) 20:28-33. doi:10.1111/IGC.0b013e3181bda1cb
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 2:161-74. doi:10.1038/nrc745
10. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta (2005) 1755:37-69. doi:10.1016/j.bbcan.2005.03.001
11. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta (2012) 1825:29-36. doi:10.1016/j.bbcan.2011.10.001
12. Boyd RS, Balkwill FR. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer (1999) 80:315-21. doi:10.1038/sj.bjc.6690357
13. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst (2002) 94:1134-42. doi:10.1093/jnci/94.15.1134
14. Drew AF, Blick TJ, Lafleur MA, Tim EL, Robbie MJ, Rice GE, et al. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice. Gynecol Oncol (2004) 95:437-48. doi:10.1016/j.ygyno.2004.08.032
15. Autio-Harmainen H, Karttunen T, Hurskainen T, Höyhtyä M, Kauppila A, Tryggvason K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest (1993) 69:312-21.
16. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer (1994) 58:50-6. doi:10.1002/ijc.2910580110
17. Afzal S, Lalani N, Foulkes WD, Boyce B, Tickle S, Cardillo MR, et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest (1996) 74:406-21.
18. Afzal S, Lalani EN, Poulsom R, Stubbs A, Rowlinson G, Sato H, et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol (1998) 29:155-65. doi:10.1016/S0046-8177(98)90226-X
19. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis (1999) 17:799-808. doi:10.1023/A:1006723011835
20. Westerlund A, Apaja-Sarkkinen M, Höyhtyä M, Puistola U, Turpeenniemi-Hujanen T. Gelatinase A-immunoreactive protein in ovarian lesions - prognostic value in epithelial ovarian cancer. Gynecol Oncol (1999) 75:91-8. doi:10.1006/gyno.1999.5533
21. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol (2000) 77:369-76. doi:10.1006/gyno.2000.5806
22. Behrens P, Rothe M, Florin A, Wellmann A, Wernert N. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med (2001) 8:149-54. doi:10.3892/ijmm.8.2.149
23. Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer (2001) 37:2040-9. doi:10.1016/S0959-8049(01)00235-0
24. Furuya M, Ishikura H, Nemori R, Shibata M, Fujimoto S, Yoshiki T. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography. Hum Pathol (2001) 32:163-8. doi:10.1053/hupa.2001.21558
25. Wu X, Li H, Kang L, Li L, Wang W, Shan B. Activated matrix metalloproteinase-2 - a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol (2002) 84:126-34. doi:10.1006/gyno.2001.6477
26. Okamoto T, Niu R, Yamada S. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary. Mol Hum Reprod (2003) 9:569-75. doi:10.1093/molehr/gag074
27. Torng PL, Mao TL, Chan WY, Huang SC, Lin CT. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol (2004) 92:559-67. doi:10.1016/j.ygyno.2003.11.011
28. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res (2006) 12:1707-14. doi:10.1158/1078-0432.CCR-05-2338
29. Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer (2007) 109:332-40. doi:10.1002/cncr.22415
30. Sillanpää S, Anttila M, Suhonen K, Hämäläinen K, Turpeenniemi-Hujanen T, Puistola U, et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol (2007) 28:280-9. doi:10.1159/000110426
31. Sillanpää S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol (2007) 104:296-303. doi:10.1016/j.ygyno.2006.09.004
32. Périgny M, Bairati I, Harvey I, Beauchemin M, Harel F, Plante M, et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 129:226-31. doi:10.1309/49LA9XCBGWJ8F2KM
33. Hałon A, Nowak-Markwitz E, Donizy P, Matkowski R, Maciejczyk A, Gansukh T, et al. Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. J Histochem Cytochem (2012) 60:491-501. doi:10.1369/0022155412446978
34. Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Daraï E. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep (2012) 27:1049-57. doi:10.3892/or.2011.1608
35. Grelewski PG, Bar JK. The role of p53 protein and MMP-2 tumor/stromal cells expression on progressive growth of ovarian neoplasms. Cancer Invest (2013) 31:472-9. doi:10.3109/07357907.2013.820320
36. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis (2003) 20:161-9. doi:10.1023/A:1022696012668
37. Chen H, Wang L, Beretov J, Hao J, Xiao W, Li Y. Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis (2010) 27:557-69. doi:10.1007/s10585-010-9345-9
38. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 3:932-42. doi:10.1038/nrm977
39. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer. Clin Biochem (2004) 37:541-8. doi:10.1016/j.clinbiochem.2004.05.013
40. Borgfeldt C, Casslén B, Liu CL, Hansson S, Lecander I, Astedt B. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer (1998) 79:588-95. doi:10.1002/(SICI)1097-0215(19981218)79:6<588::AID-IJC6>3.0.CO;2-W
41. Borgfeldt C, Hansson SR, Gustavsson B, Måsbäck A, Casslén B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer (2001) 92:497-502. doi:10.1002/ijc.1215
42. Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, et al. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol (2009) 114:265-72. doi:10.1016/j.ygyno.2009.04.031
43. Al-Hassan NN, Behzadian A, Caldwell R, Ivanova VS, Syed V, Motamed K, et al. Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia (2012) 14:259-70. doi:10.1593/neo.12442
44. Steffan JJ, Koul HK. Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor. Cancer Lett (2011) 310:109-17. doi:10.1016/j.canlet.2011.06.011
45. Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, et al. Ets-1 mRNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res (2001) 7:551-7.
46. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res (2003) 9:1412-9.
47. Ferrandina G, Scambia G, Fagotti A, D'Agostino G, Benedetti Panici P, Carbone A, et al. Immunoradiometric and immunohistochemical analysis of cathepsin D in ovarian cancer: lack of association with clinical outcome. Br J Cancer (1998) 78:1645-52. doi:10.1038/bjc.1998.737
48. Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer. Ann Oncol (1999) 10:1335-41. doi:10.1023/A:1008352502465
49. Lösch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol (2004) 92:545-52. doi:10.1016/j.ygyno.2003.11.016
50. Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A, et al. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol (2004) 92:881-6. doi:10.1016/j.ygyno.2003.11.017
51. Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, et al. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions. Am J Clin Pathol (2005) 123:360-8. doi:10.1309/PTBB5BPCKX8K9V69
52. Kauppila S, Saarela J, Stenbäck F, Risteli J, Kauppila A, Risteli L. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. Am J Pathol (1996) 148:539-48.
53. Zhu GG, Risteli L, Mäkinen M, Risteli J, Kauppila A, Stenbäck F. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms. Cancer (1995) 75:1010-7. doi:10.1002/1097-0142(19950215)75:4<1010::AID-CNCR2820750417>3.0.CO;2-O
54. Menzin AW, Loret de Mola JR, Bilker WB, Wheeler JE, Rubin SC, Feinberg RF. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants. Cancer (1998) 82:152-8. doi:10.1002/(SICI)1097-0142(19980101)82:1<152::AID-CNCR19>3.0.CO;2-1
55. Roger P, Pujol P, Lucas A, Baldet P, Rochefort H. Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol (1998) 153:1579-88. doi:10.1016/S0002-9440(10)65746-X
56. Okuma E, Ohishi Y, Oda Y, Aishima S, Kurihara S, Nishimura I, et al. Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type. Oncol Rep (2010) 24:1569-76. doi:10.3892/or_00001019
57. Kato N, Motoyama T. Relation between laminin-5 gamma 2 chain and cell surface metalloproteinase MT1-MMP in clear cell carcinoma of the ovary. Int J Gynecol Pathol (2009) 28:49-54. doi:10.1097/PGP.0b013e3181808021
58. van den Brûle F, Califice S, Garnier F, Fernandez PL, Berchuck A, Castronovo V. Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest (2003) 83:377-86. doi:10.1097/01.LAB.0000059949.01480.40
59. Givant-Horwitz V, Davidson B, van de Putte G, Dong HP, Goldberg I, Amir S, et al. Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis (2003) 20:599-609. doi:10.1023/A:1027340208536
60. Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, et al. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res (2001) 7:4073-9.
61. Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope CG, et al. AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol (2003) 90:248-57. doi:10.1016/S0090-8258(03)00321-4
62. Davidson B, Goldberg I, Kopolovic J, Gotlieb WH, Givant-Horwitz V, Nesland JM, et al. Expression of angiogenesis-related genes in ovarian carcinoma - a clinicopathologic study. Clin Exp Metastasis (2000) 18:501-7. doi:10.1023/A:1011858225144
63. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, et al. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis (2002) 19:135-44. doi:10.1023/A:1014582911680
64. Ivarsson K, Ekerydh A, Fyhr IM, Janson PO, Brännström M. Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstet Gynecol Scand (2000) 79:777-84. doi:10.1034/j.1600-0412.2000.079009777.x
65. Valve E, Martikainen P, Seppänen J, Oksjoki S, Hinkka S, Anttila L, et al. Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. Int J Cancer (2000) 88:718-25. doi:10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F
66. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in human malignancies. Exp Cell Res (2011) 317:383-91. doi:10.1016/j.yexcr.2010.11.017
67. Afify AM, Ferguson AW, Davila RM, Werness BA. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Appl Immunohistochem Mol Morphol (2001) 9:309-14. doi:10.1097/00022744-200112000-00004
68. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, Kosma VM. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res (2000) 60:150-5.
69. Tuhkanen H, Anttila M, Kosma VM, Ylä-Herttuala S, Heinonen S, Kuronen A, et al. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer (2004) 109:247-52. doi:10.1002/ijc.11733
70. Kato N, Takeda J, Fukase M, Motoyama T. Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol (2010) 23:881-8. doi:10.1038/modpathol.2010.75
71. Kato N, Takeda J, Fukase M, Motoyama T. Hyalinized stroma in clear cell carcinoma of the ovary: how is it formed? Hum Pathol (2012) 43:2041-6. doi:10.1016/j.humpath.2012.02.012
72. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 15:1013-31. doi:10.1111/j.1582-4934.2010.01236.x
73. Couchman JR, Pataki CA. An introduction to proteoglycans and their localization. J Histochem Cytochem (2012) 60:885-97. doi:10.1369/0022155412464638
74. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res (2004) 10:5178-86. doi:10.1158/1078-0432.CCR-03-0103
75. Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y. Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep (2010) 23:917-25. doi:10.3892/or_00000715
76. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, et al. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol (2010) 119:114-20. doi:10.1016/j.ygyno.2010.05.029
77. Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, et al. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer (2003) 107:359-64. doi:10.1002/ijc.11423
78. Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors. Clin Cancer Res (2002) 8:1754-60.
79. Choi KU, Yun JS, Lee IH, Heo SC, Shin SH, Jeon ES, et al. Lysophosphatidic acid-induced expression of periostin in stromal cells: prognostic relevance of periostin expression in epithelial ovarian cancer. Int J Cancer (2011) 128:332-42. doi:10.1002/ijc.25341
80. Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res (2012) 18:4514-21. doi:10.1158/1078-0432.CCR-11-3224
81. Higashi T, Sasagawa T, Inoue M, Oka R, Shuangying L, Saijoh K. Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma. Jpn J Cancer Res (2001) 92:506-15. doi:10.1111/j.1349-7006.2001.tb01123.x
82. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 73:5016-28. doi:10.1158/0008-5472.CAN-13-0023
83. Yao Q, Qu X, Yang Q, Wei M, Kong B. CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer. Oncol Rep (2009) 22:541-8. doi:10.3892/or_00000469
84. Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer (1999) 85:658-68. doi:10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M
85. Do TV, Kubba LA, Antenos M, Rademaker AW, Sturgis CD, Woodruff TK. The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology (2008) 149:3809-16. doi:10.1210/en.2007-1584
86. Brown TJ, Shaw PA, Karp X, Huynh MH, Begley H, Ringuette MJ. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol (1999) 75:25-33. doi:10.1006/gyno.1999.5552
87. Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol (2000) 78:336-41. doi:10.1006/gyno.2000.5894
88. Moraitis S, Miller WR, Smyth JF, Langdon SP. Paracrine regulation of ovarian cancer by endothelin. Eur J Cancer (1999) 35:1381-7. doi:10.1016/S0959-8049(99)00131-8
89. Madsen CV, Dahl Steffensen K, Waldstrøm M, Jakobsen A. Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up. Patholog Res Int (2012) 2012:851432. doi:10.1155/2012/851432
90. Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res (2003) 9:44-51.
91. Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, et al. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer (2004) 100:2139-47. doi:10.1002/cncr.20219
92. Weigang B, Nap M, Bittl A, Jaeger W. Immunohistochemical localization of insulin-like growth factor 1 receptors in benign and malignant tissues of the female genital tract. Tumour Biol (1994) 15:236-46. doi:10.1159/000217897
93. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR. The pathophysiology of HOX genes and their role in cancer. J Pathol (2005) 205:154-71. doi:10.1002/path.1710
94. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer (2010) 10:361-71. doi:10.1038/nrc2826
95. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci (2007) 14:605-14. doi:10.1177/1933719107307781
96. Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, et al. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest (2012) 122:3603-17. doi:10.1172/JCI62229
97. Ko SY, Lengyel E, Naora H. The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol (2010) 317:112-9. doi:10.1016/j.mce.2009.12.025
98. Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, et al. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia (2006) 8:38-45. doi:10.1593/neo.05580
99. Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, et al. VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. Mol Oncol (2013) 7:513-30. doi:10.1016/j.molonc.2012.12.006
100. Tuhkanen H, Soini Y, Kosma VM, Anttila M, Sironen R, Hämäläinen K, et al. Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer (2009) 9:289. doi:10.1186/1471-2407-9-289
101. Sundfeldt K, Ivarsson K, Carlsson M, Enerbäck S, Janson PO, Brännström M, et al. The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer (1999) 79:1240-8. doi:10.1038/sj.bjc.6690199
102. Abd-Elaziz M, Moriya T, Akahira J, Nakamura Y, Suzuki T, Sasano H. Immunolocalization of nuclear transcription factors, DAX-1 and Ad4BP/SF-1, in human common epithelial ovarian tumors: correlations with StAR and steroidogenic enzymes in epithelial ovarian carcinoma. Int J Gynecol Pathol (2005) 24:153-63. doi:10.1097/01.pgp.0000155075.75209.42
103. Ahmed N, Riley C, Quinn MA. An immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours. Br J Cancer (2008) 98:1415-24. doi:10.1038/sj.bjc.6604306
104. Campbell CL, Guardiani R, Ollari C, Nelson BE, Quesenberry PJ, Savarese TM. Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol Oncol (2001) 80:121-7. doi:10.1006/gyno.2000.6064
105. Coffelt SB, Waterman RS, Florez L, Höner zu Bentrup K, Zwezdaryk KJ, Tomchuck SL, et al. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer (2008) 122:1030-9. doi:10.1002/ijc.23186
106. Lau TS, Chung TK, Cheung TH, Chan LK, Cheung LW, Yim SF, et al. Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. J Pathol (2014) 232:43-56. doi:10.1002/path.4258
107. Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, et al. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget (2010) 1:329-38.
108. Erez N, Glanz S, Raz Y, Avivi C, Barshack I. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun (2013) 437:397-402. doi:10.1016/j.bbrc.2013.06.089
109. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, et al. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia (2013) 15:409-20. doi:10.1593/neo.121228
110. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 103:16472-7. doi:10.1073/pnas.0605752103
111. Acquati F, Lualdi M, Bertilaccio S, Monti L, Turconi G, Fabbri M, et al. Loss of function of ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. Proc Natl Acad Sci U S A (2013) 110:8140-5. doi:10.1073/pnas.1222079110
112. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer (1997) 74:57-63. doi:10.1002/(SICI)1097-0215(19970220)74:1<57::AID-IJC10>3.0.CO;2-F
113. Goff BA, Paley PJ, Greer BE, Gown AM. Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol (2001) 81:18-24. doi:10.1006/gyno.2000.6105
114. Arts HJ, de Jong S, Hollema H, ten Hoor K, van der Zee AG, de Vries EG. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol (2004) 92:794-800. doi:10.1016/j.ygyno.2003.11.054
115. Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, et al. Perturbation of the tumor necrosis factor - related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res (2005) 11:8585-91. doi:10.1158/1078-0432.CCR-05-1276
116. Erkinheimo TL, Sivula A, Lassus H, Heinonen M, Furneaux H, Haglund C, et al. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecol Oncol (2005) 99:14-9. doi:10.1016/j.ygyno.2005.04.047
117. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer (2006) 5:62. doi:10.1186/1476-4598-5-62
118. Green JA, Robertson LJ, Clark AH. Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer (1993) 68:235-9. doi:10.1038/bjc.1993.321
119. Hall GH, Turnbull LW, Richmond I, Helboe L, Atkin SL. Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. Br J Cancer (2002) 87:86-90. doi:10.1038/sj.bjc.6600284
120. Henriksen R, Dizeyi N, Abrahamsson PA. Expression of serotonin receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in ovary and in ovarian tumours. Anticancer Res (2012) 32:1361-6.
121. Katsetos CD, Stadnicka I, Boyd JC, Ehya H, Zheng S, Soprano CM, et al. Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status. Am J Pathol (1998) 153:469-80. doi:10.1016/S0002-9440(10)65590-3
122. Khin EE, Kikkawa F, Ino K, Suzuki T, Shibata K, Kajiyama H, et al. Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma. Int J Gynecol Pathol (2003) 22:175-80. doi:10.1097/00004347-200304000-00010
123. Lu JJ, Zheng Y, Kang X, Yuan JM, Lauchlan SC, Pike MC, et al. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol (2000) 79:158-68. doi:10.1006/gyno.2000.5928
124. Saw YT, Yang J, Ng SK, Liu S, Singh S, Singh M, et al. Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer (2012) 12:329. doi:10.1186/1471-2407-12-329
125. Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, et al. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis (2014) 31:101-10. doi:10.1007/s10585-013-9614-5
126. Fu S, Dong L, Sun W, Xu Y, Gao L, Miao Y. Stromal-epithelial crosstalk provides a suitable microenvironment for the progression of ovarian cancer cells in vitro. Cancer Invest (2013) 31:616-24. doi:10.3109/07357907.2013.849723
127. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet (2008) 40:650-5. doi:10.1038/ng.117
128. Kataoka F, Tsuda H, Arao T, Nishimura S, Tanaka H, Nomura H, et al. EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy. Genes Chromosomes Cancer (2012) 51:300-12. doi:10.1002/gcc.21916
129. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov (2012) 2:1100-8. doi:10.1158/2159-8290.CD-12-0206
130. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 9:654-9. doi:10.1038/ncb1596
131. Cho JA, Park H, Lim EH, Kim KH, Choi JS, Lee JH, et al. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol Oncol (2011) 123:379-86. doi:10.1016/j.ygyno.2011.08.005
132. Lili LN, Matyunina LV, Walkerm LD, Benigno BB, McDonald JF. Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma. Biomed Res Int (2013) 2013:846387. doi:10.1155/2013/846387
133. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res (2013) 19:961-8. doi:10.1158/1078-0432.CCR-12-2243
134. Morotti M, Becker CM, Menada MV, Ferrero S. Targeting tyrosine-kinases in ovarian cancer. Expert Opin Investig Drugs (2013) 22:1265-79. doi:10.1517/13543784.2013.816282
135. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One (2011) 6:e28077. doi:10.1371/journal.pone.0028077